MARKET

DERM

Dermira
DERM
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-3.5549
10.99
70.59
1,022,272,125.00
About DERM
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The Company’s portfolio consists of QBREXZA and Lebrikizumab. QBREXZA is a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients. QBREXZA is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Lebrikizumab is an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that the Company is developing for the treatment of moderate-to-severe atopic dermatitis.
More

DERM News

More
Antibody Therapies Take the Spotlight as Covid-19 ��Plan B��
bloomberg.com · 15h ago
Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
seekingalpha · 04/05 23:55
Largest Insider Trades of the Week
GuruFocus.com · 02/23 22:23
Lilly Completes Acquisition of Dermira
PR Newswire · 02/20 13:55
Will Eczema Drug Dupixent Transform Sanofi?
MotleyFool.com · 02/13 12:00
(DERM) Alert: Johnson Fistel Continues Investigation of Proposed Sale of Dermira, Inc. for $19.30
GlobeNewswire · 02/07 18:04
CSFL, DLPH, DERM, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
GlobeNewswire · 02/05 01:00
Benzinga's Top Upgrades, Downgrades For February 3, 2020
Upgrades
Benzinga · 02/03 14:55

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Dermira stock information, including NASDAQ:DERM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DERM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DERM stock methods without spending real money on the virtual paper trading platform.